Background
==========

Human cervical carcinoma *KB-3*cells, representing a subclone of human HeLa cells, are highly sensitive to most chemotherapeutic drugs, clone with high efficiency, growing rapidly [@B1], [@B2]. Vinblastine*(VBL),* as a microtubule inhibitor, is an important antitumor agent that induces *G~2~/M* arrest and subsequent apoptosis in a wide variety of cell lines [@B3]. It was well known that *VBL* treatment caused the down-regulation of *p53* and its target *p21* and up-regulation of tumor necrosis factor alpha and *Bak* in *KB-3* cells, identifying these genes as putative targets of vinblastine-inducible *AP-1*, which demonstrated that *VBL* -inducible *AP-1* played a destructive, proapoptotic role and regulated the expression of a specific subset of target genes [@B4]. *p21* was also confirmed to play a protective role in *VBL*-induced apoptosis in *KB-3* cells through a c-Jun regulated pathway [@B5]. Repression of proangiogenic and metastatic factors (*VEGF*, *bFGF*, *MMP2*, and *MMP9*) was also detected in *VBL*-treated cancer cells [@B6]. However, the networks of affecting gene expression programs and the molecular mechanisms of antitumor of this microtubule inhibitor that link G2/M arrest and apoptosis in *VBL*-treated cervical cancer are poorly understood.

In our previous studies, 49 genes were down-regulated when *VBL*-resistant *KB-v1* cells were subjected to lower dose or depletion of *VBL* and *DNA* microarray is a very useful tool to detect drug response targets in cancer treatment [@B7]. Thus, in view of the complex array of genetic factors contributing to *VBL* treatment of *KB-3* cells, *cDNA* microarray should be useful for examining the drug response in cancer. Identification of transcription factor (TF) target genes would help for elucidating the transcriptional control of the *VBL-*triggering gene expression programs. Thus, these analyses may ultimately enable the use of signature expression profiles of drug treatment to predict response to *VBL*, further to improve our understanding of mechanisms of microtubule inhibitor in human cervical carcinoma cancer *KB-3* cells.

Methods
=======

Cytotoxicity assay
------------------

The sulforhodamine B (SRB) assay standard procedures were used [@B8]. *KB-3* cells were purchased from the American Type Culture Collection and cultured in DMEM supplemented with 10% heat-inactivated fetal calf serum and the antibiotics penicillin and streptomycin. In this assay, *KB-3* cells were plated in 96-well culture plates (10^4^ cells/well) and were grown overnight at 37^o^C in a 5% CO~2~ incubator. *VBL* was then added to the wells to achieve a final concentration ranging from 10^-6^ to 10^-4^M. Control wells were prepared by adding 100 μl culture medium. The plates were incubated at 37^o^C in a 5% CO~2~ incubator for 48 h. After adding 50 μl of 50% trichloroacetic acid for 10 min at room temperature, the plates were then put at 4^o^C for 4 h and the supernatant were removed, washed 5 times with H~2~O. Then, SRB was added to each well for 30 minutes. Unbound dye was removed by four washes with 1% acetic acid. The protein-bound dye was extracted with 10 mM Tris base at a wavelength of 515 nm. The *LD~50~* and *LD~30~* were determined from the plots of percent viability vs. dose of compound added.

Cell cycle analysis
-------------------

To determine cell cycle distribution, 5 x 10^5^ cell were plated in 60-mm dishes, treated with 2.5 x 10^-4^ µM of vinblastine for 0, 2, 4, 8, 12, 24, and 48 h. Cells were then collected by trypsinization, fix in 95% ethanol, wash in 1% BSA-PBS, resuspended in 1 μg/ml of RNase and 50 μg/ml of PI, incubated for 30 min in the dark at 37^o^C, and analyzed by flow cytometry using a FACSCalibur. The data were analyzed using the ModFit *DNA* analysis program as described previously [@B9].

Gene expression profiling
-------------------------

RNA was isolated with Trizol LS (Invitrogen, Carlsbad, CA, USA) and purified using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). RNA quality was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, DE, USA). Total RNA from each sample was labelled using a Low Input Labeling Kit (Agilent Technologies), which involves reverse transcribing the mRNA to produce cDNA and then transcribing in the presence of Cy3-CTP or Cy5-CTP to produce labelled cRNA from pancreatic cancer cell lines was paired with differentially labelled cRNA from *KB-3* cells or *VBL*-treated KB-3 cells and hybridized to a 44K Whole Human Genome Oligo Microarray (Agilent Technologies) at 60 °C for 17 h according to the manufacturer\'s protocol. To reduce systematic bias, dye-swap hybridizations were performed for each cell line, and the resulting data were combined with analysis, in which dye assignment was reversed in the second hybridization in Agilent arrays.

Microarray data and pathway analysis
------------------------------------

The microarray data were represented as the antilog ratio of gene expression measures of *VBL* treated *KB-3* cells to untreated *KB-3* cells. The data were normalized and analyzed using Partek Genomics Solution software, as reported in our previous studies [@B10]. We used the Ingenuity Pathway Analysis (IPA) tool to determine the enriched canonical pathways on the basis of differential gene expression.

Identification of transcription factor (TF) target genes
--------------------------------------------------------

Previously, we developed a bioinformatics tool CMGRN to identify target gene of TFs and to construct gene regulatory networks, that has been successfully applied in cancer dataset [@B11]. This method is based on Bayesian hierarchical model with Gibbs sampling implementation to calculate joint conditional probability that genes is regulated by TFs. It is able to integrate both gene expression profiles with binding data of TFs, and to predict target genes of TFs [@B11]. Here, we applied this methodology to integrate expression data of the differentially expressed genes (fold change at least 1.5) from the *VBL*-treated microarray experiment and the binding data of four TFs, *NFKB1*, *RELA*, *AP1* and *TP53* derived from Yan et al [@B12]. As a result, we will predict target genes of the four TFs and then infer the transcriptional gene regulatory networks.

Northern blotting
-----------------

Total cellular *RNA* of untreated or *VBL*-treated *KB-3* cells was isolated as described previously [@B7], run on a 1% agarose gel (15 g per gel lane) containing 2.2 M formaldehyde, and transferred to a nitrocellulose membrane. Membrane was dried at room temperature, and *RNA* was cross-linked by UV irradiation in a Stratalinker (Stratagene). Hybridization was performed in ExpressHyb Hybridization buffer (CLONTECH) containing 1 x 10^6^ cpm/ml of ^32^P-labeled *cDNA*probe (*ID1, IER3, KRT-7*, *FN14* and *β-actin*) at 65^o^C for 2 h. Blots were washed in 2 x SSC and 0.1% SDS for 20 min, followed by a wash at 50^o^C in 0.2 x SSC and 0.1% SDS for 20 min.

Results
=======

Flow cytometry analysis of the effect of vinblastine on *KB-3* cells
--------------------------------------------------------------------

First, we tested the cytotoxicity of vinblastine in human cervical carcinoma *KB-3* cells using Sulforhodamine B (SRB) assay as described previously [@B8]. After *KB-3* cells were treated with *VBL* for 48 h, the median lethal dose (*LD~50~*) and the concentration of vinblastine at which 30% cell death was reached (*LD~30~*) in*KB-3* cells were 6.8 x 10^-4^ µM and 2.5 x 10^-4^ µM, respectively. The flow cytometry assay provides information regarding cell cycle phase sensitivity to apoptosis is based on bivariate analysis of their DNA content [@B9]. Next, the concentration of *LD~30~* was selected for analyses assessing the DNA content of vinblastine-treated *KB-3* cells, which was examined via propidium iodide (PI) staining and flow cytometry. At 0, 2, 4, 8, 12, 24, and 48 h post-treatment with 2.5 x 10^-4^ µM of vinblastine, *KB-3*cells arrested predominately at *G2/M* phase of the cell cycle and the number of cells in the *G1* phase had diminished (Fig. [1](#F1){ref-type="fig"}). With a longer duration of treatment (24 h), a much greater percentage of *KB-3* cells at *G2/M* phase. These results indicate that *KB-3* arrested at *G2/M* in response to vinblastine treatment.

Gene clustering analysis showing the differentially expressed genes in *VBL* treated *KB-3*cells in a time-dependent manner
---------------------------------------------------------------------------------------------------------------------------

The *VBL* response gene candidates were selected based on the patterns from a heat-map figure (Fig. [2](#F2){ref-type="fig"}) from the 73 normalized gene lists via Partek Genomic Suite. The red is for the up-regulated genes, blue is for down-regulated genes, white is for the missing data in a time point, which were from differently expressed genes in *KB-3* cells treated with 2.5 x 10^-4^ µM of vinblastine at 0, 2, 4, 8, 12, 16, 24, and 48 h, and identified to change in the transcriptome at a normal cutoff value ≥ ± 1.5-fold in 80% tested samples. Hierarchical clustering has the advantage that it is simple and the results can be easily visualized [@B13], and was used to partition data into two groups that have similar expression patterns (Fig. [2](#F2){ref-type="fig"}). These classes of genes could be distinguished into those whose *m*RNA levels remained induced for much longer (Fig. [2](#F2){ref-type="fig"}, cluster A) and those that responded early and whose induction was transient (Fig [2](#F2){ref-type="fig"}. cluster B), which included *IER3, SCO2, SP140, ID1, DUSP6, ADRM1, U2AF1, NUDEL, SLC26A6, BCAA, PPID, SKD1, SPHK1*, and *SGK*. Over-expressed genes in *MDR KB-v1* cells can also be found in cluster A, which showed gradually increasing gene expression in *VBL* treatment of *KB-3* cells as a function of time, including the genes that responded later (*KRT 7, KRT 17, FN14, UGT2B7, ITGA5*, and *CD63*) that appeared to be related to drug resistance involving cell wall metabolism, drug modification, and signal transduction [@B7]. The transcriptional response to vinblastine suggests a multifaceted role for *KB-3* cells in the physiology of drug metabolism.

Northern blot analysis was used to verify the array hybridization data
----------------------------------------------------------------------

Northern blot analysis of *ID1, IER3, KRT-7*,*FN14,*and β-actin was performed on *RNA* prepared from *KB-3*cells that were treated with 2.5 x 10^-4^ µM *VBL*for 0, 2, 4, 8, 12, 16, and 24 h and demonstrated that *ID1, IER3, KRT-7*, and*FN14*were deregulated in *KB-3*cells treated with *VBL* compared to *β-actin* as control (Fig. [3](#F3){ref-type="fig"}). Northern blot analysis of deregulated genes in *KB-3* cells treated with *VBL* verified the array hybridization data.

Functional networks and pathways of *VBL*-induced stress response in human cervical carcinoma *KB-3* cells were analyzed by the Ingenuity Pathway Analysis (IPA)
----------------------------------------------------------------------------------------------------------------------------------------------------------------

The genetic networks and cellular pathways were derived using the IPA program by analyzing 73 genes that were differentially expressed in *VBL*-treated *KB-3* cells. A more comprehensive network and pathway analysis of all deregulated genes revealed their association with four important network functions and five critical canonical pathways, all of which are relevant to *VBL*-treated *KB-3* cells. The differently expressed genes constituted about half the total molecules involved and the network-associated cellular functions and included those related to dermatological diseases and conditions, inflammatory disease, inflammatory response, energy production, cellular development, digestive system development and function, embryonic development, organ development, cancer, and cellular movement in *VBL*- treatment of cells (Table [1](#T1){ref-type="table"}). They belong to five canonical signaling pathways that are commonly deregulated in *VBL*treatment (Table [2](#T2){ref-type="table"}). Although only 14 (*HSPA8, PSMD11, PSMC1, HLA-C, PSMD1, PSMD8, RHOC, ITGA5, RHOF, ACTG1, MSN, MYH9, CLDN1*, and *CAPN2*) were deregulated in *VBL*-treated *KB-3* cells with the protein ubiquitination, *RhoGDI* signaling, integrin signaling, agranulocyte adhesion and biapedesis, and actin nucleation signaling pathways, which play a role in in controlling cancer cell growth, microtubule inhibition, and the stress response of *VBL-* treated *KB-3* cells.

Transcriptional gene regulatory network in *VBL*-treated cells
--------------------------------------------------------------

It has been demonstrated that some oncogenic or tumor suppresser TFs are implicated in affecting gene expression programs in cervical cancer, such as *NF-κB*[@B14], [@B15], *AP1*[@B4], [@B14], and *TP53*[@B16]. In order to elucidate how these cancer-related TFs affect the response of *VBL-*treated *KB-3* cells, we employed a newly developed bioinformatics method to identify their target genes [@B11]. As shown in Table [3](#T3){ref-type="table"}, we display the predicted target genes of *AP1*, *NFKB1*, *RELA*, and *TP53*. Some target genes have been validated in previous studies, for example, *CDKN1A (p21), DUSP5, IER3*,*ITGA5*, *RPS27L* and *SOD2* (Table [3](#T3){ref-type="table"}). We constructed a transcriptional gene regulatory network controlled by the four TFs (Fig. [4](#F4){ref-type="fig"}). Noticed is that nine genes are co-targeted by oncogenic (*AP1*, *NFKB1* and *RELA*) and tumor suppresser TFs (*TP53*), and involve biological processes apoptosis (*CDKN1A*and *SPHK1*), calcium-activated neutral proteinase (*CAPN2*), epidermis development (*EMP1, ACTG1, KRT14, KRT15*and*KRT17*), and tumor-associated antigen (*MAGED2*). By contrast, the oncogenic TFs also regulate genes related with ubiquitin-protein modification (*PSMD11*and*PSMD1*), apoptosis (*IEG3*), and cell adhesion (*ITGA5* and *MSN*). This result indicates a possibility of transcriptional gene regulation that mediates the *VBL*-induced response in the cancer cells.

Discussion
==========

In this study, first, cytotoxicity studies and the flow cytometry assay provided information regarding the cytotoxicity of microtubule inhibitor in *KB-3* cells and cell cycle phase sensitivity to apoptosis is based on bivariate analysis of their *DNA* content. The *DNA* content of untreated and *VBL*-treated *KB-3* cells was examined via PI staining and flow cytometry. At 12 h post-treatment with 2.5 x 10^-4^ µM of *VBL* (*LD~30~*), *KB-3* cells were arrested predominately at *G2/M*phase of the cell cycle and *G1* phase was apparently decreased (Fig. [1](#F1){ref-type="fig"}). Under a longer duration of treatment, a much greater percentage of *KB-3* was arrested at *G2/M* phase. The result indicated that *KB-3*arrested at *G2/M*in response to *VBL*. At the same time, the hierarchical clustering analysis revealed that *RPS27L, KRT17, FN14, UGT2B7, MYH9, CD63, ARHC, MT1E, KRT7, CDKN1A, PLAT*, and*ITGA5* were responsible for *KB-3* cells arrested predominately at *G2/M* phase of the cell cycle with 2.5 x 10^-4^ µM vinblastine, which were highly overexpressed in *VBL-*treated *KB-3*cells that responded later including those that control the cell cycle, *DNA* repair, and drug resistance. In these later response genes, *RPS27L*-expressing *LoVo* cells ceased *DNA* synthesis and apoptotic activity, and elevated *RPS27L* may improve the prognoses of certain CRC patients by enhancing the *DNA* repair capacity of their colonic cells [@B17]. *CDKN1A*, as a negative regulator of cell proliferation and *DNA* replication, plays additional and fundamental roles in other important pathways, including regulation of transcription, apoptosis and *DNA* repair [@B18]. *UGT2B7* is an enzyme responsible for detoxification of xenobiotics, as one of the most active UDP-glucuronosyltransferases, involved in drug metabolism and in maintaining homeostasis of endogenous compounds [@B19]. The expression of keratins is highly dependent on the state of cell development and differentiation and varies within different types of epithelia [@B20]-[@B22]. For example, the incidence of a positive expression for *KRT7* and *KRT17* was significantly higher in desmoplastic malignant mesothelioma than in fibrous pleuritis [@B23]. Fibroblast growth factor-inducible 14 (*FN14*) protein expression was associated with the invasive and metastatic potential of *NSCLC* and promotes hepatocyte growth factor receptor (*HGFR/MET*)-driven cell invasion [@B24]. Our Northern blot validation of gene expression profiles confirmed that *KRT-7* and *FN14* were upregulated genes that responded later in *KB-3* cells.

On the other hand, Figure [2](#F2){ref-type="fig"} also shows that Cluster B of genes in the transcriptional program of *KB-3* cells in early response to vinblastine treatment share similar expression patterns in transcript levels, which *m*RNA levels increase at 2, 4, and 8 h with vinblastine treatment, includes *IER3, ID1, SCO2, SP140, DUSP6, ADRM1, U2AF1, NUDEL, SLC26A6, BCAA, PPID, SKD1, SPHK1*, and *SGK*, which are known or likely to be involved in stress response, apoptosis, and PI3K/Akt signal transduction pathways. *IER3*(early response gene immediate early response 3), which is induced by various stimuli, such as growth factors, cytokines, ionizing radiation, viral infection, and other types of cellular stress, plays a complex and to some extent contradictory role in cell cycle control and apoptosis [@B25]. The lack of *IER3* expression is associated with a deregulation of the *NF-κB* and *PI3K/Akt* pathways [@B26], [@B27], which represents a novel mechanism of *Nrf2*regulation that may be lost in tumors and by which *IER3* exerts its stress-adaptive and tumor-suppressive activity [@B28]. Additionally, inhibitor of *DNA* binding (*ID*) family members are key regulatory proteins in a wide range of developmental and cellular processes and function by inhibiting target proteins that include the basic helix-loop-helix transcription factors [@B29]. *ID1* and *ID3* function together to govern colon cancer-initiating cell self-renewal through *p21* driven cell-cycle restriction [@B30]. Based on the bioinformatics model analysis, we demonstrated that four major TFs (*AP1*, *NFKB1*, *RELA*, and *TP53*) and the downstream genes likely form regulatory networks to modulate genes expression programs related with the *VBL*-induced response in cervical cancer cells. Two members of *NF-κB*, *RELA* and *NFKB1*, can regulate *IER3* and *p21*, providing evidence for involvement of this oncogenic TF in response of *KB-3* cells to *VBL* through targeting apoptosis signaling. Our Northern blot analyses further confirmed that *IER3* and *ID1* were upregulated genes those responded early in *KB-3* cells.

Last, we demonstrated that 14 genes, deregulated in *VBL*-treated *KB-3* cells, were involved in five signaling pathways including protein ubiquitination pathway (*HSPA8, PSMD11, PSMC1, HLA-C, PSMD1, PSMD8*), *RhoGDI* signaling (*RHOC, ITGA5, RHOF, ACTG1*and*MSN*), agranulocyte adhesion and biapedesis (*MYH9, CLDN1, ITGA5, ACTG1* and *MSN*), integrin signaling (*RHOC, ITGA5, CAPN2, RHOF*and *ACTG10*), and actin nucleation by *ARP-WASP* complex (*RHOC, ITGA5, RHOF*) (Table [2](#T2){ref-type="table"}). Gene network analysis reveals that cancer-related TFs are able to regulate these pathway genes, such as *PSMD1, PSMD11, ITGA5* and *MSN* (Fig. [4](#F4){ref-type="fig"}). These functional pathways will help us understand the response of human cervical carcinoma to the biological effects of microtubule inhibitor as chemotherapy.

In summary, the present results represent an important advancement and provide a sound basis for further exploration, but we also recognize that *in vitro* results almost certainly represent a distorted and incomplete rendering of the normal physiological response of *KB-3* cells to microtubule inhibitor. Transcriptional profiles and pathway analysis offer an opportunity to generate functional data on a genome-wide scale. Thus, mediating protein ubiquitination, *RhoGDI* signaling, and integrin signaling pathways may have a direct and effective impact on human cervical carcinoma treatment with microtubule inhibitor.
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![Effect of vinblastine (*VBL*) on cellular DNA content. *KB-3* cells untreated and treated with 2.5 x 10^-4^ µM of vinblastine for 2, 4, 8, 12, 24, and 48 h. Cells were subjected to DNA content analysis by flow cytometry with PI staining. A-D: *KB-3* cells treated with 2.5 x 10^-4^ µM of *VBL* for 0, 2, 12 and 24h. E: Data analysis of Effect of *VBL* on cellular DNA content in *KB-3* cells treated with 2.5 x 10^-4^ µM of *VBL* for 0, 2, 4, 8, 12, 24, and 48 h.](jcav06p0930g001){#F1}

![Cluster image showing the different classes of gene expression profiles. Five hundred thirty-six genes whose RNA levels changes in response to 2.5 x 10^-4^ µM of vinblastine were selected. This subset of genes was clustered hierarchically into groups on the basis of the similarity of their expression profiles. The graphs show the average expression profiles for the genes in the corresponding cluster A and B.](jcav06p0930g002){#F2}

![Northern Blots analysis of *ID1, IER3, KRT-7*and*FN14*, and *ß-actin* was used to normalize the RNA quantity in each sample (A). Analyzed the quantification of the mRNA expression levels of *ID1*, *IER3*, *KRT-7* and *FN14* those normalized to *ß-actin* in *KB-3* cells treated with vinblatine (B).](jcav06p0930g003){#F3}

![Transcriptional gene regulatory network in *VBL*-treated *KB-3* cell. Triangle nodes represent four TFs *AP1*, *NFKB1*, *RELA* and *TP53*. Circle nodes refer to target genes of at least two TFs. Orange nodes refer to genes jointly regulated by TP53 and other TFs.](jcav06p0930g004){#F4}

###### 

Genetic networks associated with *VBL*-treated *KB-3* cells.

  Top 4 VBL networks                                                                    Score   Focus molecules   Molecules in network
  ------------------------------------------------------------------------------------- ------- ----------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dermatological diseases and conditions, inflammatory disease, inflammatory response   42      19                19S proteasome, 20s proteasome, 26s Proteasome, Actin, **ADRM1**, Alpha tubulin, ATPase, **CD63**, Cytokeratin, ENaC, ERK1/2, **ID1, IER3, KRT7, KRT14, KRT15, KRT17**, Mlc, **MYH9**, Myosin, **POLK**, PP2A, **PSMC1**, PSMD, **PSMD1**, **PSMD8, PSMD11, RACGAP1, RHOC**, Rock, Smad, **SMAD2**, Ubiquitin, **VPS4B, WNK1**
  Energy production, cellular development, digestive system development and function    31      15                **ABCF1, ANXA3**, ATG4D, C1orf50, Calmodulin, **DDX5**, ERK, FAM216A, **FBXO9**, GDAP2, **HLA-C**, HNF1A, HNF4A, **LOC102724594/U2AF1**, **MRPL19, MRPL33**, MTRF1L, ORMDL2, **PAM**, Pka, **PLP2, PRMT3**, RNF44, SLC35D1, SLC7A6OS, SNX11, **SP140, TAGLN2**, TMUB2, **TPM4**, UBC, **UGT2B7**, ZNF155, ZNF442, ZNF586
  Embryonic development, organ development,                                             28      14                **ACTG1, AKR1B1**, Alpha catenin, **ANXA4**, caspase, CD3, **CDKN1A**, Clathrin, cytochrome C, estrogen receptor, F Actin, Hdac, Histone h3, Histone h4, **HSPA8**, IL12 (complex), Insulin, Interferon alpha, Jnk, **LGALS3BP**, **MAGED2, MBD1, MSN**, NFkB (complex), Notch, P38 MAPK, PI3K (complex), **PPID**, Pro-inflammatory Cytokine, Ras homolog, **RHOF**, RNA polymerase II, **RPS3, RPS27L, SGK1**
  Cancer, cellular movement                                                             23      12                Akt, Alp, Ap1, **AURKA**, calpain, **CAPN2**, Cg, **CLDN1**, Creb, Cyclin A, **DUSP5**, Fibrinogen, Focal adhesion kinase, FSH, IL1, **ITGA5**, LDL, Lh, Mek, **MT1E, MT1L**, NMDA Receptor, **NT5E**, p85 (pik3r), Pdgf (complex), PDGF BB, Pkc(s), **PLAT**, PLC gamma, Ras, **SLC26A6, SOD2, SPHK1**, Tgf beta, VegfF

###### 

Top 5 canonical pathways involving genes that are differently expressed in *VBL*- treated *KB-3* cells, as determined by Ingenuity Pathway Analysis.

  Top 5 Canonical Pathways               P value    Ratio      Molecules
  -------------------------------------- ---------- ---------- -------------------------------------------
  Protein Ubiquitination Pathway         1.31E-04   2.35E-02   HSPA8, PSMD11, PSMC1, HLA-C, PSMD1, PSMD8
  RhoGDI Signaling                       1.91E-04   2.89E-02   RHOC, ITGA5, RHOF, ACTG1, MSN
  Agranulocyte Adhesion and Diapedesis   2.88E-04   2.65E-02   MYH9, CLDN1, ITGA5, ACTG1, MSN
  Integrin Signaling                     3.90E-04   2.48E-02   RHOC, ITGA5, CAPN2, RHOF, ACTG1
  Actin Nucleation                       6.84E-04   5.36E-02   RHOC, ITGA5, RHOF

###### 

Transcription factor target genes in *VBL*-treated tumor cells**.**

  Gene symbol   AP1                      NFKB1                    RELA                     TP53
  ------------- ------------------------ ------------------------ ------------------------ ------------------------
  ACTG1                                  predicted target                                  predicted target
  AKR1B1                                 predicted target         predicted target         
  CAPN2         predicted target         predicted target                                  predicted target
  CD63          predicted target         predicted target                                  
  CDKN1A        ***validated target***   ***validated target***   ***validated target***   ***validated target***
  CLDN1                                  predicted target                                  
  DUSP5                                                                                    ***validated target***
  EMP1          predicted target                                                           predicted target
  HLA-C                                  predicted target                                  
  HSPA8                                  predicted target                                  
  IER3                                   ***validated target***   ***validated target***   
  ITGA5         predicted target         ***validated target***   ***validated target***   
  KCNK1                                  predicted target                                  
  KRT14         predicted target                                                           predicted target
  KRT15                                                           predicted target         predicted target
  KRT17                                  predicted target                                  predicted target
  LASP1                                  predicted target                                  
  LGALS3BP                                                                                 predicted target
  MAGED2        predicted target         predicted target                                  predicted target
  MORF4L2       predicted target                                                           
  MSN                                    predicted target         predicted target         
  MT1E                                   predicted target                                  
  MYH9                                   predicted target                                  
  MYO1C         predicted target                                                           
  PAM           predicted target         predicted target                                  
  PLP2          predicted target         predicted target         predicted target         
  PSMC1         predicted target                                                           
  PSMD1         predicted target         predicted target                                  
  PSMD11        predicted target         predicted target                                  
  PSMD8                                                                                    predicted target
  RAB31         predicted target         predicted target         predicted target         
  RPS27L                                                                                   ***validated target***
  SDC4                                   predicted target         predicted target         
  SOD2                                                                                     ***validated target***
  SPHK1         predicted target         predicted target                                  predicted target
  STC2                                                            predicted target         
  TAGLN2                                 predicted target                                  
  TPM4                                   predicted target                                  
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